Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Increases By 35.0%

CalciMedica, Inc. (NASDAQ:CALC) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 93,300 shares, a growth of 35.0% from the January 31st total of 69,100 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 40,600 shares, the short-interest ratio is currently 2.3 days.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of CalciMedica in a report on Tuesday.

Hedge Funds Weigh In On CalciMedica

Hedge funds and other institutional investors have recently modified their holdings of the company. Cetera Investment Advisers grew its stake in shares of CalciMedica by 37.1% in the fourth quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after purchasing an additional 4,566 shares during the last quarter. PVG Asset Management Corp purchased a new stake in CalciMedica in the 3rd quarter worth approximately $67,000. Atria Investments Inc grew its position in shares of CalciMedica by 136.5% in the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after buying an additional 15,296 shares during the last quarter. Corient Private Wealth LLC purchased a new position in shares of CalciMedica during the fourth quarter valued at approximately $135,000. Finally, Renaissance Technologies LLC bought a new position in shares of CalciMedica during the fourth quarter valued at approximately $153,000.

CalciMedica Price Performance

Shares of CalciMedica stock opened at $2.13 on Thursday. The stock has a market capitalization of $28.72 million, a P/E ratio of -1.97 and a beta of 1.20. The business’s 50 day simple moving average is $2.77 and its two-hundred day simple moving average is $3.44. CalciMedica has a one year low of $1.86 and a one year high of $6.27.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.